Business
BridgeBio Oncology is developing orally bioavailable small-molecule oncology inhibitors, including KRAS G12C and panKRAS programs.
BridgeBio Oncology remained pre-revenue as losses and cash burn increased, while equity improved after financing.
The read at a glance✓ Audited against SEC data
- Business mix — KRAS-focused oncology pipelineNote
- Revenue — No revenue reportedNote
- Losses — Net loss widened 80.5%Watch
- Cash — Free cash flow fell to -$114.5MWatch
- Balance sheet — Equity rose to $411.1MOK
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman-Z, Beneish-M, and earnings-quality unavailableNote
Leadership changes
From BridgeBio Oncology Therapeutics, Inc.'s own filings, the day they're filed.
- Michelle Doig · member · departureeff. 2026-06-16
- Eli Wallace · Directors · departureeff. 2026-04-23
- Marc Cobo · principal accounting officer · appointmenteff. 2026-04-21
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BridgeBio Oncology Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.